What Accenture gets wrong in Healthcare
Pharmaceutical technology operates under FDA 21 CFR Part 11 — the regulation that makes every electronic record and signature in a clinical or manufacturing context a compliance artifact with legal weight. Accenture's pharma practice understands the regulation well enough to produce a gap assessment. Understanding it well enough to build an architecture that enforces it is a different discipline.
The staffing pyramid destroys pharmaceutical technology engagements. A validated system — GxP-compliant, Part 11-auditable, with full electronic batch records — requires engineers who have built validated systems before. The audit trail is not a feature you add at the end. It is an architectural pattern that shapes every data model, every API design, and every UI component. Accenture's junior offshore developers, executing specifications written by a part-time senior architect, do not have this institutional knowledge.
Clinical trial systems are particularly vulnerable to this failure mode. A Phase III trial generates millions of data points with regulatory chain-of-custody requirements. A system that loses audit trail integrity mid-trial does not produce a warning — it produces an FDA inquiry, a protocol deviation, and potentially a complete response letter that delays approval by years.
What we deploy instead
Our pharmaceutical engineering teams are qualified on FDA 21 CFR Part 11, GxP validation, and the specific technical architecture of compliant clinical and manufacturing systems. They have built and validated systems that survived FDA inspections — not just passed internal gap assessments.
Every system we deploy for a pharmaceutical client is designed with Part 11 audit trail integrity from the first data model. The ALICE enforcement platform validates compliance at every commit. The validation documentation is generated automatically — not assembled by a parallel compliance workstream the week before submission.
FDA 21 CFR PART 11 and HIPAA built into the architecture from day one — enforced automatically by ALICE at every commit.
Fixed-price engagements. Production system in 8-20 weeks. No discovery phase. No change orders.
Domain-qualified engineers with healthcare experience. The senior engineer who scopes the engagement is the senior engineer who delivers it.
Full source code and documentation transferred at close. No licensing. No managed services dependency.
The compliance difference
FDA 21 CFR Part 11, GxP validation, HIPAA for patient-adjacent systems. Accenture produces compliance documentation. We produce validated systems — there is a decisive difference when the FDA audits your clinical trial data.
What switching from Accenture looks like
Pharmaceutical technology engagement: 12-20 weeks for a validated production system. Team: 8-14 engineers with GxP qualification, 1 validation engineer. Fixed price. Full IP transfer including validation documentation.
Architecture review and scope definition. We review existing deliverables and identify gaps.
Scope locked, team assembled, first sprint underway. Working code from week two.
First production milestone — a working integration or system component, not a document.
Full IP transfer. Source code, documentation, operational runbooks. Your team runs the system.
Failed Vendor Recovery Playbook
Step-by-step framework for recovering from a failed Accenture engagement — from emergency stabilisation through full re-platforming. 4-phase playbook covering stabilise, assess, transition, and normalise.